Biosynex Balance Sheet Health

Financial Health criteria checks 3/6

Biosynex has a total shareholder equity of €124.3M and total debt of €64.1M, which brings its debt-to-equity ratio to 51.6%. Its total assets and total liabilities are €241.7M and €117.4M respectively.

Key information

51.6%

Debt to equity ratio

€64.12m

Debt

Interest coverage ratio	n/a
Cash	€26.16m
Equity	€124.32m
Total liabilities	€117.41m
Total assets	€241.73m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 0DL's short term assets (€91.4M) exceed its short term liabilities (€40.8M).

Long Term Liabilities: 0DL's short term assets (€91.4M) exceed its long term liabilities (€76.6M).

Debt to Equity History and Analysis

Debt Level: 0DL's net debt to equity ratio (30.5%) is considered satisfactory.

Reducing Debt: 0DL's debt to equity ratio has increased from 17.7% to 51.6% over the past 5 years.

Debt Coverage: 0DL's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 0DL's interest payments on its debt are well covered by EBIT.

Biosynex Balance Sheet Health

Financial Health criteria checks 3/6

Key information

Recent financial health updates

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies